08/09/2021
Nota de prensa
YSIOS CAPITAL PORTFOLIO COMPANY AM-PHARMA AND KYOWA KIRIN SIGN EXCLUSIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF LLOFOTASE ALFA IN JAPAN.
• AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million.
• Kyowa Kirin gains exclusive rights to develop and commercialize ilofotase alfa in Japan.
• Ysios Capital invested in Am-Pharma in 2011 leading a 29.2M series D financing and has continued to support the company in subsequent financing rounds.
Utrecht, The Netherlands, and Tokyo, Japan, September 8, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase. Ilofotase alfa is currently being evaluated in the global pivotal REVIVAL Phase III clinical study as the potential first disease-altering treatment for sepsis-associated acute kidney injury (SA-AKI). In July of this year, AM-Pharma announced the enrollment of the first patient in Japan as part of the ongoing REVIVAL trial.
“Kyowa Kirin is a leading Japanese specialty pharmaceutical company deeply rooted in science that shares our commitment to addressing high unmet medical needs. Based on the number of successful international partnerships they have, they are the ideal partner to support the commercialization of ilofotase alfa in Japan,” stated Erik van den Berg, Chief Executive Officer at AM-Pharma. “This is a significant milestone for AM-Pharma as this agreement will optimize the commercialization of ilofotase alfa in the Japanese market and expedite our ability to bring our therapeutic candidate to a substantial patient population in Japan post-approval.”
“As an organization centered around research, development and partnerships with innovative drug discovery organizations around the globe, we are excited to initiate this relationship with AM-Pharma to potentially improve the lives of patients and families affected by sepsis-associated acute kidney injury,” added Tomohiro Sudo, Executive Officer, Head of Global Product Strategy Department at Kyowa Kirin. “Ilofotase alfa has demonstrated its therapeutic potential in AM-Pharma’s Phase II STOP-AKI study, and we look forward to being a strategic partner supporting the commercialization and thereby patient access of ilofotase alfa upon successful completion of the pivotal REVIVAL study.”
Under the terms of the agreement, AM-Pharma will receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. In addition, AM-Pharma is entitled to tiered double-digit royalties on sales and a drug supply fee. Kyowa Kirin will gain the exclusive right to develop and commercialize ilofotase alfa in Japan. AM-Pharma is responsible for the completion of the REVIVAL pivotal Phase III study, as well as a Phase I pharmacokinetics, safety and tolerability study in Japan and drug supply, whereas Kyowa Kirin will be responsible for the regulatory approval process and commercialization of ilofotase alfa in Japan.
About Ysios Capital
Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over €400 million in assets under management through its three funds.
Nuevos informes y series de datos: El Capital riesgo Informal en España 2021 / Informe de Impacto Económico y Social del Capital Privado en las operaciones de Middle Market en España. 2018 (ASCRI) / Informe de Impacto Económico y Social de los préstamos otorgados por Enisa
Otros informes destacados: Madurez del Venture Capital en España. (English version)/ Financiación de startups de Energía en España / El tiempo de las desinversiones en Private Equity en España (English version)
Webcapitalriesgo.com está patrocinada por Quantum Capital Partners
La entrada Ysios Capital portfolio company AM-Pharma and Kyowa Kirin sign exclusive license agreement for commercialization of Ilofotase alfa in Japan se publicó primero en Webcapitalriesgo.
0 Commentaires